Advances in many aspects of science including molecular biology, genomics and proteomics have resulted in significant advances in defining the causes of and new treatments for cancer. Close collaborations are needed to take advances from the laboratory into the clinic. These collaborations and resources available to conduct translational clinical research have been very productive during the current funding period. Currently, the CCSG provides funding for 0.25 FTE research nurse and 0.5 FTE clinical research specialist (CRS). The IU Simon Cancer Center has allocated this money by a process described in detail below to support investigatorinitiated Phase I and pilot studies that are highly meritorious. The ID Simon Cancer Center also provided additional funds from other sources for the conduct of these trials. We anticipate growing numbers of patients accrued to future phase I and pilot studies because of the recruitment during the current funding period of translational clinical investigators (Chiorean, Farag, Hahn, and Matei) and planned expansion of our phase I program during the next funding period. From 2004 through mid-2007, the IUSCC supported 15 clinical trials by this mechanism. Total patient accrual is to date 132. On occasion, the Center used additional funds to support individual trials. For example, additional IUSCC funds have been used to support the laboratory correlative studies associated with a trial supported by the PSR mechanism;the PSR funding has been used to support nurses and clinical research specialists. The process has been updated during the current cycle with resulting increased number of faculty conducting investigator-initiated trials. PSR support has been prioritized to protocols that will generate preliminary data that has been (or will be) used to support R21 Quick Trials and other peer-reviewed funding applications. The process to seek funding for the conduct of pilot clinical trials was updated in 2006 and is available to all IUCC members via a continuous RFA found at http://cancer.iu.edu/research/fundinq/clin trial.php. The announcement details the fact that Protocol Specific Research funding covers the cost of a core group of research nurses and data managers (clinical research specialists) for the conduct of high priority, innovative, feasibility or proof-of-principle clinical trials. The requests for funding are to be used for early-phase testing of a candidate agent or device for the prevention or treatment of cancer. Applications are received and reviewed monthly by the Clinical Research Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082709-14S3
Application #
8637216
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-09-22
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$82,641
Indirect Cost
$29,666
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Kedage, Vivekananda; Selvaraj, Nagarathinam; Nicholas, Taylor R et al. (2016) An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. Cell Rep 17:1289-1301
Nudelman, Kelly N H; McDonald, Brenna C; Wang, Yang et al. (2016) Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol 34:677-83
Hoggatt, Jonathan; Hoggatt, Amber F; Tate, Tiffany A et al. (2016) Bleeding the laboratory mouse: Not all methods are equal. Exp Hematol 44:132-137.e1
Haley, James; Tomar, Sunil; Pulliam, Nicholas et al. (2016) Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget 7:32810-20
Radovich, Milan; Solzak, Jeffrey P; Hancock, Bradley A et al. (2016) A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer 114:477-84
Li, Wei; Liu, Liangyi; Gomez, Aurelie et al. (2016) Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight 1:
Champion, Victoria L; Rawl, Susan M; Bourff, Sara A et al. (2016) Randomized trial of DVD, telephone, and usual care for increasing mammography adherence. J Health Psychol 21:916-26
Meijome, Tomas E; Baughman, Jenna T; Hooker, R Adam et al. (2016) C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis. J Cell Biochem 117:959-69
Richine, B M; Virts, E L; Bowling, J D et al. (2016) Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia. Leukemia 30:2094-2097
Masters, Andrea R; Gufford, Brandon T; Lu, Jessica Bo Li et al. (2016) Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. J Pharmacol Exp Ther 358:230-8

Showing the most recent 10 out of 220 publications